{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T06:27:22Z","timestamp":1793514442213,"version":"4.5.0"},"reference-count":91,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Prostate cancer (PCa) is one of the most common cancers among men globally. Early detection remains challenging due to the limited specificity of prostate-specific antigen (PSA) testing, which is widely used for screening and diagnosis. Emerging evidence highlights the critical role of epigenetic alterations, particularly DNA methylation and non-coding RNAs, including microRNAs and long non-coding RNAs, in PCa initiation and progression. Notably, these molecular signatures can be detected in body fluids such as blood and urine, thereby offering promising opportunities for the development of non-invasive diagnostic strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This systematic review was conducted in accordance with PRISMA 2020 guidelines (PROSPERO ID: CRD420251062598). PubMed, Web of Science, Cochrane Library, and Google Scholar were searched for studies published between 2015 and 2025 that evaluated epigenetic signatures in liquid biopsies for PCa detection. Eligible studies included case\u2013control, cohort, cross-sectional, and diagnostic accuracy designs, and data on study characteristics, biomarker types, detection methods, and diagnostic performance were independently extracted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixty-seven studies met the inclusion criteria from 5,364 screened records. These comprised 14 DNA methylation studies, 51 miRNA studies, and 2 studies with combined epigenetic signatures. Epigenetic biomarkers demonstrated consistent diagnostic potential across multiple liquid biopsy matrices, including serum, plasma, urine, and seminal fluid. GSTP1 and RASSF1A were the most frequently reported DNA methylation markers and showed moderate performance as single markers; however, multi-gene methylation panels achieved higher accuracy. In contrast, microRNAs, particularly when combined into panels, frequently exceeded PSA, especially within the diagnostic grey zone (4\u201310 ng\/mL). miR\u201321, miR\u2013141, and miR\u2013375 were the most consistently dysregulated miRNAs, although study heterogeneity remained substantial. Overall, studies integrating methylation and miRNA markers with PSA demonstrated improved sensitivity and specificity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Epigenetic biomarkers detected in liquid biopsies show strong potential as non-invasive tools for early prostate cancer diagnosis. Combining DNA methylation, miRNA markers, and PSA may improve diagnostic accuracy compared with PSA alone. Future studies should prioritise standardised methods, cross-platform validation, and large multicentre cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420251062598.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1800705","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:33:13Z","timestamp":1778214793000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Liquid biopsy\u2013based epigenetic signatures for early detection of prostate cancer: a systematic review"],"prefix":"10.3389","volume":"16","author":[{"given":"Wisdom Deborah","family":"Cleanclay","sequence":"first","affiliation":[{"name":"Department of Biochemistry, College of Science and Technology, Covenant University","place":["Ota, Nigeria"]},{"name":"Covenant Applied Informatics and Communication Africa Centre of Excellence (CApIC\u2013ACE), Covenant University","place":["Ota, Nigeria"]},{"name":"Covenant University Public Health and Wellbeing Research Cluster (CUPHWERC), Covenant University","place":["Ota, Ogun State, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irrinus Fonyuy","family":"Kintung","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, College of Science and Technology, Covenant University","place":["Ota, Nigeria"]},{"name":"Covenant Applied Informatics and Communication Africa Centre of Excellence (CApIC\u2013ACE), Covenant University","place":["Ota, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice Banadzem","family":"Kernyuy","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, College of Science and Technology, Covenant University","place":["Ota, Nigeria"]},{"name":"Covenant Applied Informatics and Communication Africa Centre of Excellence (CApIC\u2013ACE), Covenant University","place":["Ota, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina Ghislaine","family":"Yensii","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, College of Science and Technology, Covenant University","place":["Ota, Nigeria"]},{"name":"Covenant Applied Informatics and Communication Africa Centre of Excellence (CApIC\u2013ACE), Covenant University","place":["Ota, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boluwatife Oluwafemi","family":"Fagbohun","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, College of Science and Technology, Covenant University","place":["Ota, Nigeria"]},{"name":"Covenant Applied Informatics and Communication Africa Centre of Excellence (CApIC\u2013ACE), Covenant University","place":["Ota, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel Chimuebuka","family":"Amadi","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, College of Science and Technology, Covenant University","place":["Ota, Nigeria"]},{"name":"Covenant Applied Informatics and Communication Africa Centre of Excellence (CApIC\u2013ACE), Covenant University","place":["Ota, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels Nguedia","family":"Kaze","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, College of Science and Technology, Covenant University","place":["Ota, Nigeria"]},{"name":"Covenant Applied Informatics and Communication Africa Centre of Excellence (CApIC\u2013ACE), Covenant University","place":["Ota, Nigeria"]},{"name":"Afrique One Reach, Centre Suisse de Recherche Scientifique","place":["Abidjan, C\u00f4te d'Ivoire"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26167667","article-title":"Biomarkers in localized prostate cancer: From diagnosis to treatment","volume":"26","author":"Lopez-Valcarcel","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12776","article-title":"Liquid biopsy: Emergence of an alternative cancer detection method","volume":"13","author":"Law","year":"2020","journal-title":"Clin Transl Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00949","article-title":"Disparities with systemic therapies for black men having advanced prostate cancer: Where do we stand","volume":"42","author":"Gong","year":"2024","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1177\/15330338241290029","article-title":"Advancements in biomarkers of prostate cancer: A review","volume":"23","author":"Agbetuyi-Tayo","year":"2024","journal-title":"Technol Cancer Res Treat"},{"key":"B6","article-title":"Genetics, epigenetic mechanism","volume-title":"StatPearls","author":"Al Aboud","year":"2025"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-024-00991-8","article-title":"Prostate cancer epigenetics \u2014 from pathophysiology to clinical application","volume":"22","author":"Const\u00e2ncio","year":"2025","journal-title":"Nat Rev Urol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-013-0249-2","article-title":"Methylation markers for prostate cancer prognosis: A systematic review","volume":"24","author":"Chao","year":"2013","journal-title":"Cancer Causes Control"},{"key":"B9","unstructured":"Methylation of glutathione S-transferase pi 1 as an epigenetic biomarker for prostate cancer detection in black South African men"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155091","article-title":"MicroRNA-21\u2019s role in PTEN suppression and PI3K\/AKT activation: Implications for cancer biology","volume":"254","author":"Chawra","year":"2024","journal-title":"Pathol Res Pract"},{"key":"B11","unstructured":"MicroRNA-125b inhibits apoptosis and increases gemcitabine resistance by downregulating the expression of BAK1 in pancreatic ductal adenocarcinoma - Sun - Translational Cancer Research"},{"key":"B12","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41598-019-57101-7","article-title":"Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer","volume":"10","author":"Zedan","year":"2020","journal-title":"Sci Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1405267","article-title":"Emerging biomarkers for non-invasive diagnosis and treatment of cancer: A systematic review","volume":"14","author":"Zakari","year":"2024","journal-title":"Front Oncol"},{"key":"B14","unstructured":"The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy - PMC"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252010982","article-title":"Acetylation of histone H3 in cancer progression and prognosis","volume":"25","author":"Miziak","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B16","unstructured":"Clinical significance of extracellular vesicles in prostate and renal cancer - PMC"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12481","article-title":"Extracellular vesicles carry transcriptional \u2018dark matter\u2019 revealing tissue-specific information","volume":"13","author":"Dogra","year":"2024","journal-title":"J Extracell Vesicles"},{"key":"B18","unstructured":"Epigenetics marker for cancer detection: A promising approach"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-018-0564-2","article-title":"Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients","volume":"10","author":"Moreira-Barbosa","year":"2018","journal-title":"Clin Epigenet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-025-01810-z","article-title":"Diagnostic relevance of Humanin, GAS5 and miR-21\/miR-103 in prostate disease risk stratification","volume":"25","author":"Coradduzza","year":"2025","journal-title":"Clin Exp Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174459","article-title":"Increased sensitivity of detection of RASSF1A and GSTP1 DNA fragments in serum of prostate cancer patients: Optimisation of diagnostics using OBBPA-ddPCR","volume":"13","author":"Friedemann","year":"2021","journal-title":"Cancers"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3233\/HAB-200424","article-title":"Investigation of GSTP1 and epigenetic regulators expression pattern in a population of Iranian patients with prostate cancer","volume":"28","author":"Mohammadi","year":""},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.21037\/apm-20-1496","article-title":"Diagnostic value of DACT-2 methylation in serum of prostate cancer patients","volume":"10","author":"Lan","year":"2021","journal-title":"Ann Palliative Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14873","article-title":"Promoter methylation of MCAM, ER\u03b1 and ER\u03b2 in serum of early stage prostate cancer patients","volume":"8","author":"Brait","year":"2017","journal-title":"Oncotarget"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.240","article-title":"Serum GADD45a methylation is a useful biomarker to distinguish benign vs Malignant prostate disease","volume":"113","author":"Reis","year":"2015","journal-title":"Br J Cancer"},{"key":"B26","article-title":"Diagnostic value of GSTP1, RASSF1, and RASSF2 methylation in serum of prostate cancer patients","volume":"21","author":"Aykanli","year":"2024","journal-title":"Urol J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14184355","article-title":"Early dynamics of quantitative SEPT9 and SHOX2 methylation in circulating cell-free plasma DNA during prostate biopsy for prostate cancer diagnosis","volume":"14","author":"Krausewitz","year":"2022","journal-title":"Cancers"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16071324","article-title":"Blood-based DNA methylation analysis by multiplexed OBBPA-ddPCR to verify indications for prostate biopsies in suspected prostate cancer patients","volume":"16","author":"Friedemann","year":""},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2024.1338468","article-title":"Influential factors on urine EV DNA methylation detection and its diagnostic potential in prostate cancer","volume":"15","author":"Ding","year":"2024","journal-title":"Front Genet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/life14081024","article-title":"Methylated DNA markers in voided urine for the identification of clinically significant prostate cancer","volume":"14","author":"Shah","year":"2024","journal-title":"Life-Basel"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0218950","article-title":"Screening of urine identifies PLA2G16 as a field defect methylation biomarker for prostate cancer detection","volume":"14","author":"Jarrard","year":"2019","journal-title":"PloS One"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.32113\/wcrj_20199_1384","article-title":"Assessment of glutathione-S-transferase (GSTP1) methylation status is a reliable molecular biomarker for early diagnosis of prostatic intraepithelial neoplasia","volume":"6","author":"Varriale","year":"2019","journal-title":"World Cancer Res J"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24749","article-title":"LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA","volume":"84","author":"Abramovic","year":""},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.17305\/bjbms.2022.7497","article-title":"Methylation pattern of caveolin-1 in prostate cancer as potential cfDNA biomarker","volume":"23","author":"Skara","year":"2023","journal-title":"Biomolecules Biomedicine"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5873056","article-title":"Circulating miRNAs as biomarkers for prostate cancer diagnosis in subjects with benign prostatic hyperplasia","volume":"2020","author":"Jin","year":"2020","journal-title":"J Immunol Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaa111","article-title":"Prostate cancer early diagnosis: Circulating microRNA pairs potentially beyond single microRNAs upon 1231 serum samples","volume":"22","author":"Liu","year":"2021","journal-title":"Brief Bioinform"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.afju.2018.11.006","article-title":"microRNA-141 as a diagnostic and prognostic biomarker for prostate cancer in Egyptian population: Pilot study","volume":"24","author":"Ali","year":"2018","journal-title":"Afr J Urol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1515\/tjb-2018-0198","article-title":"Diagnostic performance of microRNAs in the circulation in differential diagnosis of BPH, chronic prostatitis and prostate cancer","volume":"44","author":"Dulgeroglu","year":"2019","journal-title":"Turkish J Biochemistry-Turk Biyokimya Dergisi"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-01875-0","article-title":"A preliminary study of micro-RNAs as minimally invasive biomarkers for the diagnosis of prostate cancer patients","volume":"40","author":"Giglio","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2021.2009413","article-title":"Diagnostic significance of microRNA-1255b-5p in prostate cancer patients and its effect on cancer cell function","volume":"12","author":"Zhao","year":"2021","journal-title":"Bioengineered"},{"key":"B41","doi-asserted-by":"publisher","first-page":"6653","DOI":"10.1038\/s41598-018-24424-w","article-title":"A plasma biomarker panel of four microRNAs for the diagnosis of prostate cancer","volume":"8","author":"Matin","year":"2018","journal-title":"Sci Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-02382-w","article-title":"Evaluation of the diagnostic value of a three-miRNA panel in prostate cancer: A discovery and validation study","volume":"16","author":"Li","year":"2025","journal-title":"Discover Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2514930","article-title":"Testing the accuracy of a three-miRNA panel for the detection of primary prostate cancer: a discovery and validation study","volume":"21","author":"Wang","year":"2025","journal-title":"Future Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2024.1371441","article-title":"A panel based on three-miRNAs as diagnostic biomarker for prostate cancer","volume":"15","author":"Chen","year":"2024","journal-title":"Front Genet"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.58207","article-title":"Discovery and validation of novel microRNA panel for non-invasive prediction of prostate cancer","volume":"16","author":"Kumari","year":"2024","journal-title":"Cureus J Med Sci"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/genes15050584","article-title":"Evaluation of miR-148a-3p and miR-106a-5p as biomarkers for prostate cancer: Pilot study","volume":"15","author":"Coman","year":"2024","journal-title":"Genes (Basel)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262017","article-title":"Evaluation of micro-RNA in extracellular vesicles from blood of patients with prostate cancer","volume":"16","author":"Kim","year":"2021","journal-title":"PloS One"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.151","article-title":"A circulating miRNA assay as a first-line test for prostate cancer screening","volume":"114","author":"Sharova","year":"2016","journal-title":"Br J Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10040188","article-title":"Profiling of circulating microRNAs in prostate cancer reveals diagnostic biomarker potential","volume":"10","author":"Fredsoe","year":"2020","journal-title":"Diagnostics"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/genes14101884","article-title":"Detection of cancer-associated gene mutations in urinary cell-free DNA among prostate cancer patients in South Africa","volume":"14","author":"Temilola","year":"2023","journal-title":"Genes"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2017.02.018","article-title":"Diagnostic and prognostic microRNA biomarkers for prostate cancer in cell-free urine","volume":"4","author":"Freds\u00f8e","year":"2018","journal-title":"Eur Urol Focus"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2018.296681","article-title":"Independent validation of a diagnostic noninvasive 3-microRNA ratio model (uCaP) for prostate cancer in cell-free urine","volume":"65","author":"Freds\u00f8e","year":"2019","journal-title":"Clin Chem"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2024.14770","article-title":"Single-centre, retrospective, evaluator-blinded, pilot and pivotal clinical trials: Assessing the mirCaP Kit (hsv2-miR-H9\/hsa-miR-3659) as a diagnostic marker for prostate cancer in patients with PSA levels in the gray zone","volume":"29","author":"Kim","year":"2025","journal-title":"Oncol Lett"},{"key":"B54","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/CMAR.S272140","article-title":"Identification of urinary exosomal miRNAs for the non-invasive diagnosis of prostate cancer","volume":"13","author":"Li","year":"2021","journal-title":"Cancer Manage Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.21873\/cgp.20383","article-title":"Combination of urinary miR-501 and miR-335 with current clinical diagnostic parameters as potential predictive factors of prostate biopsy outcome","volume":"20","author":"Juracek","year":"2023","journal-title":"Cancer Genomics Proteomics"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10080578","article-title":"Evaluation of microRNAs as non-invasive diagnostic markers in urinary cells from patients with suspected prostate cancer","volume":"10","author":"Borkowetz","year":"2020","journal-title":"Diagnostics"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2016.5095","article-title":"Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone","volume":"13","author":"Ivan Salido-Guadarrama","year":"2016","journal-title":"Mol Med Rep"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8124","article-title":"Non-invasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles","volume":"7","author":"Koppers-Lalic","year":"2016","journal-title":"Oncotarget"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.5812\/ijcm.110014","article-title":"Non-invasive prostate cancer detection by measuring expression level of miR-21 and miR-214 in urine","volume":"14","author":"Emamvirdizadeh","year":"2021","journal-title":"Int J Cancer Manage"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.4111\/icu.20200488","article-title":"Urinary microRNA-1913 to microRNA-3659 expression ratio as a non-invasive diagnostic biomarker for prostate cancer","volume":"62","author":"Byun","year":"2021","journal-title":"Invest Clin Urol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"13772","DOI":"10.1038\/s41598-019-50172-6","article-title":"Semen miRNAs contained in exosomes as non-invasive biomarkers for prostate cancer diagnosis","volume":"9","author":"Barcel\u00f3","year":"2019","journal-title":"Sci Rep"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/iub.1733","article-title":"Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among Egyptian patients with prostate cancer","volume":"70","author":"Zidan","year":"2018","journal-title":"IUBMB Life"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2015.4014","article-title":"Increased oncogenic microRNA-18a expression in the peripheral blood of patients with prostate cancer: A potential novel non-invasive biomarker","volume":"11","author":"Al-Kafaji","year":"2016","journal-title":"Oncol Lett"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8778","article-title":"Blood-based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer-risk stratification","volume":"16","author":"Al-Kafaji","year":"2018","journal-title":"Oncol Lett"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3390\/jcm4071369","article-title":"A circulating microRNA signature as a biomarker for prostate cancer in a high risk group","volume":"4","author":"Kelly","year":"2015","journal-title":"J Clin Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/biom12101366","article-title":"Prostate cancer-associated miRNAs in saliva: First steps to an easily accessible and reliable screening tool","volume":"12","author":"Luedemann","year":"2022","journal-title":"Biomolecules"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.628094","article-title":"MicroRNA-940 as a potential serum biomarker for prostate cancer","volume":"11","author":"Rajendiran","year":"2021","journal-title":"Front Oncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"74","DOI":"10.5213\/inj.2015.19.2.74","article-title":"Urinary microRNAs of prostate cancer: Virus-encoded hsv1-miR-H18 and hsv2-miR-H9-5p could be valuable diagnostic markers","volume":"19","author":"Yun","year":"2015","journal-title":"Int Neurourology J"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-018-1938-2","article-title":"Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition","volume":"50","author":"Porzycki","year":"2018","journal-title":"Int Urol Nephrol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2016_417","article-title":"Analysis of circulating miRNAs 21 and 375 as potential biomarkers for early diagnosis of prostate cancer","volume":"63","author":"Gao","year":"2016","journal-title":"Neoplasma"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.prnil.2023.06.002","article-title":"Screening and validation of novel serum panel of microRNA in stratification of prostate cancer","volume":"11","author":"Manoj","year":"2023","journal-title":"Prostate Int"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00900","article-title":"Circulating microRNAs as biomarkers for prostate cancer detection and metastasis development prediction","volume":"9","author":"Bidarra","year":"2019","journal-title":"Front Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3459","article-title":"Circulating plasma miR222-3P status and its potential diagnostic performance in prostate cancer","volume":"24","author":"Heydari","year":"2022","journal-title":"J Gene Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1515\/tjb-2021-0154","article-title":"miR-221, miR-650 and miR-4534 as diagnostic markers in prostate cancer and their relationship with lymphatic invasion","volume":"47","author":"Hekimler Ozturk","year":"2022","journal-title":"Turkish J Biochemistry-Turk Biyokimya Dergisi"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgy167","article-title":"Circulating microRNAs combined with PSA for accurate and non-invasive prostate cancer detection","volume":"40","author":"Mello-Grand","year":"2019","journal-title":"Carcinogenesis"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S119027","article-title":"Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: Evaluation of potential diagnostic and prognostic role","volume":"9","author":"Cochetti","year":"2016","journal-title":"Oncotargets Ther"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.11441","article-title":"MicroRNA panel in serum reveals novel diagnostic biomarkers for prostate cancer","volume":"9","author":"Zhang","year":"2021","journal-title":"PeerJ"},{"key":"B78","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12943-017-0726-4","article-title":"Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes","volume":"16","author":"Rodr\u00edguez","year":"2017","journal-title":"Mol Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6094409","article-title":"Diagnostic value of prostate-specific antigen combined with plasma miRNA-149 expression in patients with prostate cancer based on experimental data and bioinformatics","volume":"2022","author":"Wang","year":"2022","journal-title":"Contrast Media Mol Imaging"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-01373-9","article-title":"Role of circulating microRNAs in prostate cancer diagnosis and risk stratification in the MCC Spain study","volume":"15","author":"Gomez-Acebo","year":"2025","journal-title":"Sci Rep"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3390\/cells10092372","article-title":"A new approach for prostate cancer diagnosis by miRNA profiling of prostate-derived plasma small extracellular vesicles","volume":"10","author":"Zabegina","year":"2021","journal-title":"Cells"},{"key":"B82","unstructured":"Beyond the biomarker role: prostate-specific antigen (PSA) in the prostate cancer microenvironment | Cancer and Metastasis Reviews"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20081813","article-title":"A rich array of prostate cancer molecular biomarkers: Opportunities and challenges","volume":"20","author":"Kohaar","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B84","unstructured":"Methylated septin9 (mSEPT9): A promising blood-based biomarker for the detection and screening of early-onset colorectal cancer - PMC"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3390\/life12030386","article-title":"Obtaining reliable RT-qPCR results in molecular diagnostics\u2014MIQE goals and pitfalls for transcriptional biomarker discovery","volume":"12","author":"Gr\u00e4tz","year":"2022","journal-title":"Life (Basel)"},{"key":"B86","doi-asserted-by":"publisher","first-page":"549","DOI":"10.4103\/1008-682X.179859","article-title":"Prostate cancer epigenetics and its clinical implications","volume":"18","author":"Yegnasubramanian","year":"2016","journal-title":"Asian J Andrology"},{"key":"B87","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.nbt.2019.06.007","article-title":"How standardization of the pre-analytical phase of both research and diagnostic biomaterials can increase reproducibility of biomedical research and diagnostics","volume":"53","author":"Riegman","year":"2019","journal-title":"New Biotechnol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.606400","article-title":"A review of cancer genetics and genomics studies in Africa","volume":"10","author":"Rotimi","year":"2021","journal-title":"Front Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13236051","article-title":"Pathogen-induced epigenetic modifications in cancers: Implications for prevention, detection and treatment of cancers in Africa","volume":"13","author":"Zune","year":"2021","journal-title":"Cancers"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153968","article-title":"Potential of miRNAs in plasma extracellular vesicle for the stratification of prostate cancer in a South African population","volume":"15","author":"Temilola","year":"2023","journal-title":"Cancers"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3390\/jmp7020015","article-title":"Leveraging Epigenetic Biomarkers and CRISPR-Cas12a for Early Prostate Cancer Detection in Sub-Saharan Africa: Opportunities and Challenges","volume":"7","author":"Nguedia","year":"2026","journal-title":"J Mol Pathol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1800705\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:33:31Z","timestamp":1778214811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1800705\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":91,"alternative-id":["10.3389\/fonc.2026.1800705"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1800705","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"article-number":"1800705"}}